Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation.

@article{Inoue2015FatostatinAS,
  title={Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation.},
  author={Kazuki Inoue and Yuuki Imai},
  journal={Biochimica et biophysica acta},
  year={2015},
  volume={1852 11},
  pages={
          2432-41
        }
}
Osteoclast differentiation is associated with both normal bone homeostasis and pathological bone diseases such as osteoporosis. Several transcription factors can regulate osteoclast differentiation, including c-fos and Nfatc1. Using genome-wide DNase-seq analysis, we found a novel transcription factor, SREBP2, that participates in osteoclast differentiation in vitro. Here, we asked whether SREBP2 actually plays a role in controlling bone metabolism in vivo. To answer this question, RAW264 cells… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Similar Papers

Loading similar papers…